The FDA Oncologic Drugs Advisory Committee July 14 voted 12-0 to recommend approval for belantamab mafodotin for relapsed or refractory multiple myeloma.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
